R&D News | pharmaphorum

News

A woman undertakes a mammogram with a female HCP

Lynparza boosts long-term survival in early breast cancer

A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later.

News

Mulvany hits the reset button at BenevolentAI

The shape of BenevolentAI following the return of co-founder Ken Mulvany has started to crystallise and could see the company return to private hands.

News

Refiling for cALD therapy on the cards after new data

Readout from NEXUS study sets up mid-2025 refiling for Minoryx and Neuraxpharm's leriglitazone for rare disease cerebral adrenoleukodystrophy (cALD).

News

Drug-digital dual therapy for depression starts phase 2

Gate Neurosciences' antidepressant apimostinel has started a proof-of-concept study to see if its efficacy can be boosted by a digital training tool.

News

uniQure rockets on map to market for Huntington's therapy

uniQure says it has reached agreement with the FDA on a pathway to accelerated approval for its much-anticipated Huntington's disease gene therapy.

News

Operating theatre with nurse and patient under anaesthetic

ASH: Stem cell transplant study exposes US zip-code lottery

Access to a stem cell transplant in the US - and the chances of surviving it - depends on social and economic factors, finds a new study.

Lynparza boosts long-term survival in early breast cancer

Mulvany hits the reset button at BenevolentAI

Refiling for cALD therapy on the cards after new data

Drug-digital dual therapy for depression starts phase 2

uniQure rockets on map to market for Huntington's therapy

ASH: Stem cell transplant study exposes US zip-code lottery

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks